DVS skips quarantine, says he has to ensure medicine supply across country

Bengaluru, May 6: The second day of liquor sales in Karnataka on Tuesday after easing of lockdown curbs saw a nearly five-fold jump in earnings, with Rs 197 crore worth spirits being sold.

According to top Excise Department officials, 4.21 lakh cases of Indian-made liquor, comprising 36.37 lakh litres, worth Rs 182 crore and 7.02 lakh litres of beer in 0.90 lakh cases worth Rs 15 crore was sold on Tuesday.

On Monday, when sales resumed in the state, Rs 45 crore worth liquor was sold.

"We had never expected such a record sale. It's unprecedented," an Excise official who did not wish to be named said.

Liquor sales had resumed in Karnataka on Monday after a 41 day gap following the lockdown due to the COVID-19 pandemic.

Mangaluru, May 23: Criticising the Karnataka government's fresh protocol for management of Covid-19 as expensive, a prominent physician in the city has demanded its withdrawal.

According to Dr B Srinivas Kakkilaya, the protocol released by the Health and Family Welfare Department on May 15 enlists unnecessary and unconfirmed tests and treatments. 

The protocol has classified Covid-19 cases into three categories and has provided for hospitalisation of all three categories of patients, from asymptomatic to the most severely ill.

In a letter to the government, Dr Kakkilaya said: "The protocol suggests several investigations to be done right on the day of admission, including blood counts, liver and renal function tests, chest X Ray, ECG, CT scan of the chest, and other special investigations, all of which, if done, will cost Rs 25,000 per patient."

"In the coming days when lakhs of patients are likely to be infected with SARS CoV2, is it necessary and feasible to hospitalise and test all these patients at Rs 25,000 per person," he questioned.

The treatment options suggested in the protocol are also surprising, he pointed out. "The protocol recommends choloroquine, azithromycin, oseltamivir, zinc and vitamin C for all patients, from asymptomatic to the severely ill, and also anti coagulant injections for many patients. All these would cost at least Rs 5,000 per patient. For severe cases of Covid-19, many unproven and experimental treatments have been suggested, which are very expensive and highly questionable," Dr Kakkilaya notes.

Therefore, this protocol, he asserted was not evidence based and likely to do more harm than good. He said these unnecessarily expensive tests and allowing private companies to conduct trials on Covid-19 patients is likely to be misused by vested interests and must be immediately withdrawn, and instead, a protocol that is evidence-based, simple and avoiding unnecessary expenses, must be developed.